Allogene Therapeutics Announces Participation in Seven Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., April 12, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that management plans to participate in seven upcoming investor conferences.
Canaccord Genuity Horizons in Oncology Virtual Conference
Thursday, April 14, 2022
8:00AM PT/11:00AM ET
BofA Securities 2022 Healthcare Conference
Tuesday, May 10, 2022
8:00AM PT/11:00AM ET
2022 RBC Capital Markets Global Healthcare Conference
Tuesday, May 17, 2022
8:30AM PT/11:30AM ET
Jefferies Global Healthcare Conference
Wednesday, June 8-Thursday, June 9, 2022
Details to be posted to the Company’s website
Goldman Sachs 43rd Annual Global Healthcare Conference
Monday, June 13, 2022
Details to be posted to the Company’s website
2022 Truist Securities Cell Therapy Symposium
Tuesday, June 28, 2022
Details to be posted to the Company’s website
Stifel Virtual Cell Therapy Conference
Thursday, June 30, 2022
8:30AM PT/11:30AM ET
Any available webcasts will be posted to the Company's website at www.allogene.com under the Investors tab in the News and Events section. Following the live webcast, a replay will be available on the Company's website for approximately 30 days.
About Allogene Therapeutics
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) products for cancer. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T cell candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit www.allogene.com, and follow @AllogeneTx on Twitter and LinkedIn.
Cautionary Note on Forward-Looking Statements for Allogene
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the ability to develop allogeneic CAR T products for cancer and the potential benefits of AlloCAR T. Various factors may cause differences between Allogene’s expectations and actual results as discussed in greater detail in Allogene’s filings with the Securities and Exchange Commission (SEC), including without limitation in its Form 10-K for the year ended December 31, 2021. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
AlloCAR T™ is a trademark of Allogene Therapeutics, Inc.
Allogene Media/Investor Contact:
Christine Cassiano
Chief Communications Officer
(714) 552-0326
Christine.Cassiano@allogene.com
